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Objective: To study the effect of intra-articular injection of meloxicam (Mobic) on the development of
osteoarthritis (OA) in rats and examine concomitant changes in nociceptive behavior and the expression
of mitogen-activated protein kinases (MAPKs) in articular cartilage chondrocytes.
Methods: OA was induced in Wistar rats by right anterior cruciate ligament transection (ACLT); the left
knee was not treated. The OA þmeloxicam (1.0 mg) group was injected intra-articularly in the ACLT knee
with 1.0 mg of meloxicam once a week for 5 consecutive weeks starting 5 weeks after ACLT. The
OA þ meloxicam (0.25 mg) group was treated similarly with 0.25 mg meloxicam. The sham group un-
derwent arthrotomy only and received vehicle of 0.1 mL sterile 0.9% saline injections, whereas the naive
rats in meloxicam-only groups were treated similarly with 1.0- and 0.25-mg meloxicam. Nociception was
measured as secondary mechanical allodynia and hind paw weight-bearing distribution at before (pre-)
and 5, 10, 15, and 20 weeks post-ACLT. Histopathology of the cartilage and synovia was examined 20
weeks after ACLT. Immunohistochemical analysis was performed to examine the effect of meloxicam on
MAPKs (p38, c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase (ERK)) expression
in the articular cartilage chondrocytes.
Results: OA rats receiving intra-articular meloxicam treatment showed signiﬁcantly less cartilage
degeneration and synovitis than saline-treated controls. Nociception were improved in the
OA þmeloxicam groups compared with the OA group. Moreover, meloxicam attenuated p38 and JNK but
enhanced ERK expression in OA-affected cartilage.
Conclusions: Intra-articular injection of meloxicam (1) attenuates the development of OA, (2) concom-
itantly reduces nociception, and (3) modulates chondrocyte metabolism, possibly through inhibition of
cellular p38 and JNK, but enhances ERK expression.
Crown Copyright  2013 Published by Elsevier Ltd on behalf of Osteoarthritis Research Society
International. All rights reserved.Y.-H. Jean, Address: Depart-
ospital, # 60, Da-Lan Road,
-8-7338536.
@ptch.org.tw (Y.-H. Jean).
013 Published by Elsevier Ltd onIntroduction
Osteoarthritis (OA) is the most common joint disorder and has
an immense socio-economic impact. OA is a complex disease
characterized by bone remodeling, synovium inﬂammation, and
cartilage loss. Although OA is classically deﬁned as a progressivelybehalf of Osteoarthritis Research Society International. All rights reserved.
Z.-H. Wen et al. / Osteoarthritis and Cartilage 21 (2013) 1976e1986 1977degenerative disease of articular cartilage, inﬂammation has
recently been described as playing a key role in the pathogenesis
of OA1.
Meloxicam, an enolcarboxamide derivative with an elimination
half-life (T1/2) of 20 h, inhibits prostaglandin (PG) biosynthesis
in vivo2. It preferentially inhibits the inﬂammatory cyclooxygenase
(COX)-2 over the physiological enzyme COX-13 and has a 3- to 77-
fold greater afﬁnity for COX-2 than for COX-14,5. In clinical studies,
meloxicam has demonstrated reliable efﬁcacy against both OA and
rheumatoid arthritis (RA)6,7. In chronic models of induced arthritis
and spontaneous OA in rats, meloxicam has been demonstrated to
suppress hind paw swelling8 as well as bone and cartilage
destruction9,10. Early oral treatment with meloxicam not only
ameliorates clinical signs and joint inﬂammation in acute synovitis
in horses but may also limit inﬂammation-induced cartilage
catabolism11. Coadministration of meloxicam and the inducible
nitric oxide synthase (iNOS) inhibitor aminoguanidine showed a
synergistic antinociceptive effect that might possibly reduce
gastrointestinal toxicity associated with the use of meloxicam in
mice12. Despite the widespread use of meloxicam by patients with
OA, relatively little information about its effects against nociception
and OA development in experimental OA models is available.
Mitogen-activated protein kinases (MAPKs) are important me-
diators of a variety of physiological and pathological cellular pro-
cesses, including cell death, survival, proliferation, and
migration13e16. The MAPK family consists of the p38 kinase, c-Jun
N-terminal kinase (JNK), and the extracellular signal-regulated ki-
nase 1/2 (ERK). P38 and JNK are activated in response to inﬂam-
matory cytokines, such as interleukin (IL)-1 and tumor necrosis
factor (TNF)14,17,18, while ERK mediates signaling by cytokines and
growth factors19,20. Inhibitors of MAPKs for treatment of arthritis
are under development and have shown efﬁcacy against experi-
mental arthritis and joint pain20e22. Despite many in vitro, in vivo,
and clinical studies of meloxicam and of the roles of MAPKs in
arthritis, the in vivo effects of meloxicam on cartilageMAPK activity
during the pathogenesis of OA remain unknown. In the present
study, we have investigated the effects of intra-articular injection of
meloxicam on cartilage degeneration and synovitis as assessed by
macroscopic and histological evaluation and on joint nociception as
assessed by secondary mechanical allodynia and hind paw weight-
bearing distribution in an experimental OA model in rats. More-
over, we performed immunohistochemical analysis to examine the
effect of meloxicam on MAPKs expression in the articular cartilage
chondrocytes.
Methods
Animals
The use of rats conformed to the Guiding Principles in the Care
and Use of Animals approved by the Council of the American
Physiology Society and was approved by the National Sun Yat-Sen
University Animal Care and Use Committee (approval number
96015). Three-month-old male Wistar rats (body weight ¼ 290e
315 g) were used and were maintained under climate-controlled
conditions on a 12-h lightedark cycle at 22e24C with a relative
humidity of 50e55%.
Surgical technique for induction of OA
OAwas induced in rats by anterior cruciate ligament transection
(ACLT) of the right knee; the left knee was not treated. The knees
were shaved and disinfected with betadine solution, then a medial
parapatellar incision was made in the skin, and medial arthrotomy
performed. The ACL was exposed and identiﬁed under direct visionand cut through the mid-substance. For the sham operation, the
ACL was exposed, but not transected. This procedure was modiﬁed
from the protocol described in previous studies23,24.
Experimental design and meloxicam injection
The animals were randomly allocated into six experimental
groups. The OA þ meloxicam (1.0 mg) group animals (n ¼ 6) were
injected intra-articularly in the ACLT knee with 1.0 mg of melox-
icam (Sigma, St. Louis, MO, USA) once a week for 5 consecutive
weeks starting 5 weeks after ACLT. The OA þ meloxicam (0.25 mg)
group animals (n ¼ 6) were injected intra-articularly in the ACLT
knee with 0.25 mg of meloxicam once a week for 5 consecutive
weeks starting 5 weeks after ACLT. The animals in the OA control
group (n ¼ 6) were injected with 0.1 mL of sterile 0.9% saline (as
vehicle), as described previously. The animals in the sham group
(n ¼ 6) underwent arthrotomy only and were injected with 0.1 mL
of saline, as described earlier. The meloxicam (1.0-) and (0.25 mg)
alone groups (n ¼ 6 each) consisted of naive rats injected with 1.0
and 0.25 mg of meloxicam for normal control, as described earlier.
The rats in each experimental group were injected with an equiv-
alent saline volume of 0.1 mL (or meloxicam powder dissolved in
saline to a ﬁnal volume of 0.1 mL).
Assessment of nociception
Nociception (secondary mechanical allodynia and hind paw
weight distribution) and changes in knee joint width were assessed
at ﬁve different time points: week 0, (before surgery), as well as
weeks 5, 10, 15, and 20 after surgery. Intra-articular injection
treatment with meloxicam or saline was performed at 5, 6, 7, 8, and
9 weeks after surgery (injected at ﬁve times the recommended
dosage in each rat). At 5 weeks after ACLT surgery, nociception and
changes in knee joint width were assessed 1 h prior to intra-
articular saline or meloxicam injection. The experimental animals
were habituated to the nociceptive testing environment for 60 min
daily for 3 days before baseline testing. Moreover, after intra-
articular injection of meloxicam (or saline), the animals were still
habituated to the nociceptive testing environment approximately
60 min daily, three times per week. Each rat was subjected to the
test for a minimum of three repetitions at the ﬁve time points
(before surgery, and 5, 10, 15, and 20 weeks after surgery), and the
results were averaged.
Secondary mechanical allodynia
In the secondary mechanical allodynia, the paw withdrawal
thresholds to mechanical stimulus were determined using the up-
and-down method25 by applying the calibrated von Frey ﬁlaments
(North Coast Medical, Inc. Morgan Hill, CA, USA). The diameters of
the ﬁlaments were proportional to a logarithm of the force exerted,
and the perceived intensity could therefore be measured on linear
and interval scales. The withdrawal threshold was determined us-
ing Chaplan’s “up-and-down” method involving the use of alter-
nate large and small ﬁlaments to determine the 50% withdrawal
threshold25. Each von Frey ﬁlaments was applied to the plantar
surface of the paw for 5 s. The von Frey ﬁlament was applied to each
paw for ﬁve trials at approximately 3-min intervals.
Weight-bearing distribution test
The effect of joint damage on the weight distribution through
the right (OA) and the left (contralateral) knees was measured us-
ing a Dual Channel Weight Averager (Singa Technology Corpora-
tion, TW) which independently measures the weight bearing to
Time after ACLT surgery (week)
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Fig. 1. Time course of the antiallodynic and joint width change effects of meloxicam in
the ACLT-OA nociceptive model. (A) The force required to elicit hind paw withdrawal in
the mechanical allodynia assessment was signiﬁcantly greater for the OA þmeloxicam
(1.0 mg) and OA þ meloxicam (0.25 mg) groups than for the OA rats 10, 15, and 20
weeks after surgery. Data shown represent the mean (95% conﬁdence interval) of the
ipsilateral hind paw of each group. (B) The time course of the difference between
contralateral and ipsilateral weight bearing (g) for 20 weeks after surgery. Signiﬁcant
differences were noted between the OA and OA þ meloxicam (1.0 mg) and
OA þmeloxicam (0.25 mg) groups 10, 15, and 20 weeks after surgery. (C) The widths of
the bilateral hind-limb knee joints were measured in each rat pre- and 5, 10, 15, and 20
weeks post-ACLT. Data shown represent the mean (95% conﬁdence interval) as the
difference in knee widths between the values at each time point and at time zero
(before surgery). a, P < 0.05 compared with the sham group; b, P < 0.05 compared
with the OA group.
Z.-H. Wen et al. / Osteoarthritis and Cartilage 21 (2013) 1976e19861978each hind paw. In brief, changes in hind paw weight-bearing dis-
tribution between the left (contralateral control) and right (OA)
limbs were utilized as an index of joint pain in the knees with
surgically induced OA26,27. The force exerted by each hind-limb
(measured in grams) was averaged over a 5-s period. Each data
point is the mean of three 5-s readings. The hind paw weight dis-
tribution was expressed as the difference in weight between the
contralateral and ipsilateral limbs.
Change of knee joint width and gross morphological and
histopathological examination of joints
Changes in knee joint width were measured bilaterally using
calipers (AA847R, Aesculap, AG&CO, KG, German) before and 5, 10,
15, and 20 weeks after surgery. The width of the knee joint was
measured from the medial to the lateral aspect of the knee joint (at
approximately the level of the medial and lateral joint lines).
Twenty weeks after surgery, the rats were sacriﬁced by deep
anesthesia with sodium pentobarbital (50 mg/kg). The joints were
cut 0.5 cm above and below the joint line, ﬁxed with 10% neutral
buffered formalin for 3 days, and then decalciﬁed for 2 weeks with
buffered 12.5% ethylenediaminetetraacetic acid (EDTA)/formalin
solution. Standardized serial sections (thickness, 5 mm) were ob-
tained at the medial and lateral midcondylar level in the sagittal
plane. Ten sections of specimens were prepared from each knee.
Cartilage was stained with hematoxylin/eosin (H/E) and with
safranin-O/fast green stains in order to assess general morphology
andmatrix proteoglycans. The sections stainedwith safranin-O/fast
greenwere deparafﬁnized in xylene and hydrated in a graded series
of solutions of ethanol in distilled water. The staining solution 0.5%
(w/v) safranin-O (Lot 713466; Fisher Scientiﬁc, Fairlawn, NJ) was
prepared in 0.1 mol/l of sodium acetate buffer at a pH of 4.6. The
sections were stained for 10 min. Subsequently, the sections were
dehydrated in ethanol solutions and cleared in xylene28. Immedi-
ately after sacriﬁce, each knee was examined for gross morphologic
changes or cartilage lesions using previously described methods29.
Microscopic examination was used to grade the articular cartilage
according to the Osteoarthritis Research Society International
(OARSI) grading system30. Synovial membrane specimens were
carefully dissected from the suprapatellar pouch and the tibiofe-
moral compartments, and embedded in parafﬁn, and 10 slides
prepared from each knee were stained with H/E for synovitis scores
assessment by histology31.
Immunohistochemical staining for p38, JNK, and ERK
Cartilage specimens were processed for immunohistochemical
analysis as previously described22,32,33. For immunohistochemistry,
after deparafﬁnization of the sections using xylene, followed by
rehydration with a graded series of ethanol, we quenched the
endogenous peroxidase activity of the sections by 0.3% H2O2 for
30 min, and thenwe permeabilized the sections with 0.1% Triton X-
100 in phosphate-buffered saline (PBS) for 20 min. After retrieval of
the antigen using proteinase K (20 mM; Sigma) in PBS for 20 min,
we incubated the sections with 5% normal goat serum in PBS for
30 min to decrease nonspeciﬁc adsorption. The sections were
incubated overnight at 4Cwith anti-phospho-p38 (Thr180/Tyr182,
1:100 dilution, polyclonal antibody; catalog no. 9211; Cell Signaling
Technology Inc., Beverly, MA, USA), anti-phospho-JNK (Thr183/
Tyr185, 1:100 dilution, polyclonal antibody; catalog no. 9251, Cell
Signaling Technology Inc., Beverly, MA, USA), or anti-phospho-ERK
antibodies (Thr202/Tyr204, 1:100 dilution, polyclonal antibody;
catalog no. 9101; Cell Signaling Technology Inc., Beverly, MA, USA).
Finally, after incubation with biotin-conjugated anti-rabbit IgG
(1:200 dilution; catalog no. BA-1100, Vector Laboratories Inc.,Burlingame, CA, USA) for 30 min, followed by the avidinebiotine
peroxidase complex for 30 min (Vectastain ABC kit, Vector Labo-
ratories Inc., Burlingame, CA, USA), we incubated sections with 3,30-
diaminobenzidine tetrahydrochloride (DAB; Vectastain ABC kit,
Vector Laboratories Inc, Burlingame, CA, USA) for 8 min. The
Z.-H. Wen et al. / Osteoarthritis and Cartilage 21 (2013) 1976e1986 1979negative control group received the same procedures, but with
rabbit IgG (catalog no. 011-000-003; Jackson ImmunoResearch
Laboratories Inc., West Grove, PA, USA) instead of the primary
antibody. All the sections for immunohistochemistry were
analyzed under a Leica DM-6000 CS microscope (Leica Instruments
Inc., Wetzlar, Germany) with a microscope digital camera system
(SPOT Idea 5 MP CMOS scientiﬁc color digital camera system,
Diagnostic Instruments, Inc., Sterling Heights, MI, USA).
The different antigens present in each cartilage specimen were
quantiﬁed by determining the number of positively stained chon-
drocytes in the entire thickness of cartilage, as previously
described20,32. The cartilage was divided into six microscopic ﬁelds
(three each in the superﬁcial and deep zones) (magniﬁcation,
400), and the results were averaged. Prior to evaluation of each
OA specimen, an intact cartilage surface was identiﬁed for use as a
marker for the validation of the morphometric analysis. The ﬁnal
results were expressed as the percentage of chondrocytes staining
positive for each antigen (cell score), with a maximum score of
100% for each cartilage specimen.
Data and statistical analysis
All data were presented as mean (95% conﬁdence interval). The
data passed normality and equal variance tests and analyzed by
one-way ANOVA followed by an unpaired Student’s t test with a
multiple comparison post hoc test. Signiﬁcant difference was
deﬁned as a P < 0.05.
Results
On dissection, all knees with ACLTs exhibited various degrees of
OA, as evidenced by erosions, ulcerations, and osteophyte forma-
tions in the tibial plateaus and femoral condyles. No signs of
hemarthrosis or sepsis after surgery. There were no signiﬁcant
differences in body weight between the groups over the study
period.
Nociceptive behavior (secondary mechanical allodynia and weight-
bearing distribution)
Figure 1(A) shows the effect of intra-articular meloxicam
(compared with saline) on mechanical allodynia in ACLT-induced
OA rats. The force required to produce hind paw withdrawal was
signiﬁcantly greater for the OA þ meloxicam (1.0 mg) group than
for the OA group at 10,15, and 20 weeks [(8.3 (10.3e6.3) g vs 4.6
(6.7e2.4) g, P¼ 0.008; 9.13 (12.2e6.0) g vs 4.7 (6.9e2.4) g, P¼ 0.013Table I
Macroscopic [gross cartilage damage area (%)], histological evaluation of the articular ca
Group OA OA þ meloxicam OA þ
Score (N ¼ 10) (1.0 mg) (n ¼ 10) (0.25
Gross cartilage damage area (%) 32.8 (37.23e28.37) 11.3 (13.23e9.37) 13.5 (
Comparison vs sham: P-value <0.001 <0.001 <0.00
Comparison vs OA: P-value e <0.001 <0.00
OARSI score 17.8 (20.30e15.30) 7.5 (8.36e6.64) 8.4 (9
Comparison vs sham: P-value <0.001 <0.001 <0.00
Comparison vs OA: P-value e <0.001 <0.00
Synovitis score 8.1 (9.03e7.17) 3.5 (3.86e3.14) 3.8 (4
Comparison vs sham: P-value <0.001 <0.001 0.002
Comparison vs OA: P-value e <0.001 <0.00
Data was expressed as mean (95% conﬁdence interval). For the macroscopic, OARSI and sy
saline; OA þ meloxicam (1.0 mg): ACLT-induced OA knee treated with 1.0 mg intra-arti
0.25 mg intra-articular meloxicam; Sham: rat underwent arthrotomy and received saline
meloxicam only. Meloxicam (0.25 mg) alone: naïve rat received 0.25 mg intra-articularand 8.7 (10.3e7.0) g vs 4.3 (6.7e2.0) g, P¼ 0.003, respectively) after
ACLT. The same trend was also noted in the OA þ meloxicam
(0.25 mg) group (8.7 (10.3e7.0) g vs 4.6 (6.7e2.4) g, P ¼ 0.003; 9.8
(12.6e7.1) g vs 4.7 (6.9e2.4) g, P ¼ 0.004 and 8.3 (9.9e6.8) g vs 4.3
(6.7e2.0) g, P¼ 0.004, respectively) [Fig.1(A)]. The force required to
produce hind paw withdrawal was signiﬁcantly greater for the
sham group than for the OA group at 5, 10, 15, and 20 weeks after
surgery [Fig. 1(A)].
In the weight-bearing distribution test, the difference between
the contralateral and ipsilateral limb was greater in the treatment
groups than in the sham group 5, 10, 15, and 20 weeks after ACLT
[Fig. 1(B)]. The OA þmeloxicam (1.0 mg) group showed decreasing
differences in weight distribution between the untreated left and
the injured right hind paws comparedwith the OA group 10,15, and
20 weeks after surgery [39.5 (49.6e29.4) g vs 67.5 (82.2e52.8) g,
P ¼ 0.002; 32.5 (44.6e20.4) g vs 61.3 (75.1e47.5) g, P ¼ 0.002 and
25.3 (31.2e19.5) g vs 63.3 (75.3e51.4) g, P < 0.001, respectively;
Fig. 1(B)]. The same trend was noted for the OA þ meloxicam
(0.25mg) group [38.0 (53.6e22.4) g vs 67.5 (82.2e52.8) g, P¼ 0.005;
29.0 (40.1e17.9) g vs 61.3 (75.1e47.5) g, P<0.001 and21.9 (35.5e8.2)
g vs 63.3 (75.3e51.4) g, P < 0.001, respectively; Fig. 1(B)]. The dif-
ference between the contralateral and ipsilateral weight bearing
between OA and sham groups showed signiﬁcant at 5,10,15, and 20
weeks after surgery [Fig. 1(B)]. In the present studies, there were no
differences in nociceptive behavior test results between the groups
that received meloxicam 0.25 mg alone and the sham groups.
Changes in knee joint width and gross morphologic changes [(gross
cartilage damage area (%))
As shown in Fig. 1(C), 20 weeks after induction of OA, signiﬁcant
decreases in the width of the hind-limb knee joint between the
OA þ meloxicam (1.0 mg) and OA groups were noted 15 and 20
weeks [0.8 (1.0e0.7)mmvs1.2 (1.4e1.0)mm, P¼0.002 and1.0 (1.1e
0.8)mmvs 1.6 (1.7e1.4) mm, P< 0.001, respectively] after ACLT. The
same trend was noted for the OA þ meloxicam (0.25 mg) group
vs the OA group 15 and 20 weeks [0.8 (1.0e0.6) mmvs 1.2 (1.4e1.0)
mm, P ¼ 0.001 and 1.0 (1.1e0.8) mm vs 1.6 (1.7e1.4) mm, P < 0.001,
respectively] after ACLT [Fig.1(C)]. In the present studies, therewere
no differences in changes in knee joint width between the groups
that received meloxicam 0.25 mg alone and the sham groups.
Gross characteristics of cartilage degeneration, such as ﬁbrilla-
tion, erosion and ulcer formation, and osteophyte formation, were
seen in the tibial plateaus and femoral condyle of the OA group.
Signiﬁcant differences in gross cartilage damage area (%) were
found between the OA, OA þ meloxicam (1.0 mg), andrtilage of the femoral condyles and tibial plateau, and the synovial tissue
meloxicam Sham Meloxicam (1.0 mg)
alone
Meloxicam (0.25 mg)
alone
mg) (n ¼ 10) (N ¼ 6) (N ¼ 4) (N ¼ 4)
16.72e10.28) 3.1 (3.94e2.26) 2.4 (3.36e1.45) 2.8 (3.60e2.00)
1 e 0.176 0.527
1 <0.001 <0.001 <0.001
.67e7.11) 2.5 (3.02e1.98) 2.1 (2.74e1.46) 1.9 (2.22e1.58)
1 e 0.219 0.055
1 <0.001 <0.001 <0.001
.37e3.23) 2.3 (3.03e1.56) 2.0 (2.80e1.20) 2.2 (2.84e1.56)
e 0.483 0.804
1 <0.001 <0.001 <0.001
novitis scores, refer to the Methods section. OA: ACLT-induced OA knee treated with
cular meloxicam; OA þ meloxicam (0.25 mg): ACLT-induced OA knee treated with
injection only. Meloxicam (1.0 mg) alone: naïve rat received 1.0 mg intra-articular
meloxicam only. *P < 0.05 vs the sham group; yP < 0.05 vs the OA group.
Z.-H. Wen et al. / Osteoarthritis and Cartilage 21 (2013) 1976e19861980OA þ meloxicam (0.25 mg) groups, and the sham group (Table I).
The quantitative analysis indicated that the cartilage damage area
was signiﬁcantly decreased in the OA þ meloxicam groups than in
the OA group (Table I). The area of the eroded cartilage surface was
reduced in the joints of the meloxicam-treated rats (Table I). The
synovial membranes from the OA group were hypertrophic andFig. 2. Histopathological evaluation of the articular cartilage and synovium membrane of the
cartilaginous layer was smooth and the cartilage matrix was consistently well stained w
disappearance of the surface layer cells (arrow), a cleft extending into the transitional and ra
specimen from the OA þmeloxicam (1.0 mg) and (D) OA þmeloxicam (0.25 mg) groups show
layer (arrow). (E) Meloxicam (1.0 mg)- and (F) Meloxicam (0.25 mg) alone groups, similar ch
the sham, (K) meloxicam (1.0 mg)-, and (L) meloxicam (0.25 mg) alone groups showed no sy
group showed a thickened synovia, with focal villi (arrow) and evidence of synovial hyperpla
the OA þ meloxicam (1.0 mg) and (J) OA þ meloxicam (0.25 mg) groups showed a lower de
magniﬁcation 100). Scale bar ¼ 200 mm.showed a reddish yellow discoloration, whereas those from the
OA þ meloxicam groups were thinner and had less-intense
discoloration (data not shown). The synovial membranes from
the sham and meloxicam-alone groups had a white luster and
transparent appearance, with no hyperemia or evidence of syno-
vitis (data not shown).knee joint 20 weeks after surgery. (A) In the sham group, the surface of the superﬁcial
ith H/E. (B) The specimen from the OA group showed decreased cartilage thickness,
dial zones, and chondrocyte hypocellularity in the transitional and radial zones. (C) The
ed mild irregularity of the surface layer, that is, the cleft in the superﬁcial cartilaginous
anges were observed as in the sham group. The synovial membrane specimen from (G)
novial-lining cell hyperplasia (within the normal limit). The specimen from (H) the OA
sia and moderate inﬁltration of mononuclear inﬂammatory cells. (I) The specimen from
gree of severity of synovitis (arrow) than those from the OA group (H/E stain, original
Z.-H. Wen et al. / Osteoarthritis and Cartilage 21 (2013) 1976e1986 1981Microscopic ﬁndings
The cartilage of the sham group had a normal histological
appearance: a thin, glistening, smooth lamina ﬁlled with ﬂattened
chondrocytes was observed [Fig. 2(A)]. Specimens from the OA
group showed obvious histological changes, including complete
disorganization, moderate-to-severe hypocellularity [Fig. 2(B)]. The
OAþmeloxicam (1.0 mg) [Fig. 2(C)] and OAþmeloxicam (0.25mg)
groups [Fig. 2(D)] demonstrated marked reduction in the severity
of the cartilage lesions: only ﬁbrillation and ﬁssures extending into
the superﬁcial layer of cartilage were observed. The cartilage of
naïve rats that received meloxicam injections (1.0 mg and 0.25 mg)
showed normal morphology [Fig. 2(E and F)]. Signiﬁcant differ-
ences in the OARSI score were found between the sham group and
the OA, OA þ meloxicam (1.0 mg), and OA þ meloxicam (0.25 mg)
groups (Table I). The OARSI scores of both the OA þ meloxicam
(1.0 mg) and OA þ meloxicam (0.25 mg) groups were signiﬁcantly
lower than that of the OA group (Table I). The synovial membranesFig. 3. Distribution of phospho-p38 protein immunoreactivity in the cartilage of the sham
immunoreactivity of phospho-p38 protein is indicated by the red-brown color (arrows). Th
sham, (B) OA, (C) OA þ meloxicam (0.25 mg), (D) meloxicam (0.25 mg) alone, and (E) negat
protein. (F) Quantitative analysis showed that meloxicam signiﬁcantly reduced the ACLT-ind
data were presented as mean (95% conﬁdence interval). (*P < 0.05 compared with the shafrom the OA group were thick, had focal villi, and showed hyper-
plasia of the lining cells and moderate inﬁltration of mononuclear
cells. The synovial membranes from the sham [Fig. 2(G)], melox-
icam (1.0 mg)- [Fig. 2(K)], or meloxicam (0.25 mg) alone [Fig. 2(L)]
groups were histologically within the normal limits, with no
synovial-lining cellular hyperplasia and only very slight cellular
inﬁltration seen in the underlying tissue. Signiﬁcant differences in
synovitis scores were found between the sham [Fig. 2(G)], and the
OA [Fig. 2(H)], OA þ meloxicam (1.0 mg) [Fig. 2(I)], and
OA þ meloxicam (0.25 mg) groups [Fig. 2(J)], as well as between
each of the OA þ meloxicam groups and OA group (Table I).
Immunohistochemical detection of p38, JNK, and ERK in articular
cartilage
The immunolocalization of phosphorylated MAPK proteins
(phospho-p38, phospho-JNK, and phospho-ERK) in cartilage spec-
imens from the sham, OA, and OA þ meloxicam (0.25 mg) groups, OA, OA þ meloxicam (0.25 mg), and meloxicam (0.25 mg) alone groups. Positive
e panels show the distribution of anti-p38 immunoreactivity in the cartilage of the (A)
ive control groups. All samples were stained with antibodies against the phospho-p38
uced increase in the number of p38-positive chondrocytes in the OA knee cartilage. The
m and OA groups; n ¼ 6 in each groups). Scale bar ¼ 100 mm.
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in Fig. 3, fewer phospho-p38-positive chondrocytes were observed
in the sham group [Fig. 3(A)] than in the OA group [Fig. 3(B)]. In the
OA group, 20 weeks after ACLT, the numbers of phospho-p38-
immunoreactive chondrocytes appeared to be increased in the
superﬁcial and transitional cartilaginous zones [Fig. 3(B)]. Melox-
icam (0.25 mg) injection inhibited OA-induced upregulation of
phospho-p38 expression in cartilage chondrocytes [Fig. 3(C)].
Meloxicam (0.25 mg) alone did not signiﬁcantly affect phospho-
p38 expression in cartilage specimens [Fig. 3(D)]. Quantiﬁcation
of the number of phospho-p38-immunoreactive cells showed sig-
niﬁcant inhibition of OA-induced upregulation of phospho-38-
positive chondrocytes in the OA þ meloxicam (0.25 mg) group
[Fig. 3(F), P¼ 0.019]. As shown in Fig. 4, only a very small number of
chondrocytes in cartilage specimens from the sham group stained
positive for phospho-JNK [Fig. 4(A)]. Phospho-JNK protein expres-
sion was clearly seen in chondrocytes within the superﬁcial and
transitional cartilage in the OA specimens, similar to the results forFig. 4. Distribution of phospho-JNK protein immunoreactivity in the cartilage of the sham
immunoreactivity of the JNK protein is indicated by the red-brown color (arrows). The panels
sham, (B) OA, (C) OA þmeloxicam (0.25 mg), (D) meloxicam (0.25 mg) alone, and (E) negativ
Quantitative analysis showed that meloxicam signiﬁcantly reduced the ACLT-induced increa
data were presented as mean (95% conﬁdence interval). (*P < 0.05 compared with the shaphospho-p38 expression [Fig. 4(B)]. The phospho-JNK protein
expressionwas signiﬁcantly increased in the OA compared with the
sham group [Fig. 4(C and F), P ¼ 0.04]. Meloxicam injection
(0.25 mg) signiﬁcantly inhibited OA-induced upregulation of
phospho-JNK expression in cartilage chondrocytes [Fig. 4(C and F),
P ¼ 0.005]. Meloxicam (0.25 mg) alone did not signiﬁcantly affect
phospho-JNK expression in cartilage specimens [Fig. 4(D)]. Fig. 5
shows the distribution of phospho-ERK-positive cells in cartilage
from the sham [Fig. 5(A)], OA [Fig. 5(B)], OAþmeloxicam (0.25 mg)
[Fig. 5(C)], and meloxicam (0.25 mg) alone groups [Fig. 5(D)]. The
number of phospho-ERK-positive chondrocytes was increased in
the OA þ meloxicam (0.25 mg) and meloxicam (0.25 mg) alone
groups compared with the OA group [Fig. 5(C), (D) and (F),
P ¼ 0.048 and P < 0.001, respectively]. Decreased phospho-ERK
expression was seen in the OA specimen 20 weeks after ACLT
[Fig. 5(E)]. No staining was observed in the phospho-p38, phospho-
JNK, or phospho-ERK negative controls for any of the treatment
groups., OA, OA þ meloxicam (0.25 mg), and meloxicam (0.25 mg) alone groups. Positive
show the distribution of anti-phospho-JNK immunoreactivity in the cartilage of the (A)
e control groups. All were stained with antibodies against the phospho-JNK protein. (F)
se in the number of phospho-JNK-positive chondrocytes in the OA knee cartilage. The
m group; n ¼ 6 in each groups). Scale bar ¼ 100 mm.
Fig. 5. Distribution of phospho-ERK protein immunoreactivity in the cartilage of the sham, OA, OA þ meloxicam (0.25 mg), and meloxicam (0.25 mg) alone groups. Positive
immunoreactivity of the phospho-ERK protein is indicated by the red-brown color (arrows). The panels show the distribution of anti-phospho-ERK immunoreactivity in the
cartilage of the (A) sham, (B) OA, (C) OA þ meloxicam (0.25 mg), (D) meloxicam (0.25 mg) alone, and (E) negative control groups. All were stained with antibodies against the
phospho-ERK protein. (F) Quantitative analysis showed that meloxicam signiﬁcantly enhanced the number of phospho-ERK-positive chondrocytes in the cartilage of the ACLT-
induced OA knees. The data were presented as mean (95% conﬁdence interval). (*P < 0.05 compared with the sham and OA groups. #P < 0.05 compared with the OA group;
n ¼ 6 in each groups). Scale bar ¼ 100 mm.
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To our knowledge, this is the ﬁrst report that intra-articular
injection of the selective COX-2 inhibitor meloxicam can atten-
uate the development of OA and concomitant nociceptive behavior
(such as secondary mechanical allodynia and altered weight-
bearing distribution) in an experimental ACLT-induced OA model
in rats. More interestingly, meloxicam inhibited p38 and JNK
expression, but enhanced ERK expression, in the articular cartilage
chondrocytes in this experimental OA model.
Meloxicam, at therapeutic concentrations, inhibits PG produc-
tion without affecting either cartilage proteoglycan production or
the production of those cytokines likely to be important in cartilage
destruction34. Meloxicam can increase the synthesis of pro-
teoglycans and hyaluronan in explants with moderate and severe
OA35. For meloxicam, the therapeutically equivalent dose to 10 mg/
kg rofecoxib is 3mg/kg36. Another report recommended therapeuticdoses for meloxicam, ranging from 0.1 mg/kg subcutaneous injec-
tion (s.c.) in cats37 to 1 or 2 mg/kg s.c. in rats38,39. In our pilot study,
we tested the 0.05-, 0.25-, and 1.0-mg meloxicam injections in the
OA and naive rats and found that only the latter two doses could
attenuate the nociceptive behaviors in the OA rats and that all the
three doses showed no detrimental effects on cartilage in the naive
rats. Thus,wechose the 0.25- and1.0-mgdoses ofmeloxicam for our
present study.
The use of once-daily dosing of many drugs, including NSAIDs, is
a current trend in medical practice. Diclofenac, celebrex, and
meloxicam can also be given once daily in the treatment of various
rheumatic disorders40e42. In the present study, one major advan-
tage of this method of delivery over the traditional oral methods is
that meloxicam applied intra-articularly could achieve the desired
concentrations in the synovial ﬂuid while maintaining a low
plasma concentration. This low systemic exposure could provide
numerous potential beneﬁts to patients, including the avoidance of
Z.-H. Wen et al. / Osteoarthritis and Cartilage 21 (2013) 1976e19861984gastrointestinal tract irritation and reduced risk of serious adverse
cardiovascular effects.
It is interesting to note that in the present study, no loss of the
meloxicam-mediated effects was observed 10 weeks after discon-
tinuation of the drugs, indicating that a short-term treatment with
meloxicam had a long-lasting effect on signs of pain and inﬂam-
mation, but it may be hypothesized that the long-term effects may
have been due to the accumulation of meloxicam during the 5
weekly intra-articular treatments. Although there is no speciﬁc
evidence to support our speculation, it is plausible that the synovial
ﬂuid concentration of meloxicam in the rats 10 weeks after treat-
ment discontinuationwas sufﬁcient to mediate the continued anti-
inﬂammatory and analgesic effects. In our future studies, our team
will continue to examine the role of meloxicam (including its blood
and synovial ﬂuid concentrations) in animal OA models.
Synovial inﬂammation also plays an important role in the OA
disease process6,43. Inﬂammatory changes associated with the ACLT
model include joint effusions and synovial membrane hyperpla-
sia23,24, which represent an important mechanism of joint pain in
patients with OA44. In the present study, moderate synovitis was
noted in the OA group, and treatment with either 1.0 mg or 0.25 mg
of meloxicam reduced both the severity of synovitis and the knee
joint width. These ﬁndings are in agreement with a previous report
that meloxicam effectively attenuated sodium urate-induced
synovitis45.
Castro et al. used a quantitative method to associate joint pain
with weight bearing in the ACLT rat model46. In the present study,
ACLT caused a painful response in the injured right hind paws of
rats, causing the animals to re-distribute their body weight in favor
of the non-injured left limb. Intra-articular administration of
meloxicam efﬁciently attenuated the secondary mechanical allo-
dynia and improved the weight-bearing distribution on the injured
right hind paw 10, 15, and 20 weeks after ACLT, suggesting that
COX-2 may be involved in OA nociception. However, the exact
mechanism by which meloxicam affects nociception in knee joint
OA requires further investigation.
P38 and JNK are typically activated by cellular stress and phos-
phorylated in response to proinﬂammatory cytokines, such as TNF-
a and IL-1b14,17,18,47; this results in activation of transcription fac-
tors, such as the activator protein-1 (AP)-1 complex48, that are
involved in expression of matrix metalloproteinases and aggreca-
nase49,50. ERK was originally implicated in regulating mitosis,
proliferation, differentiation, and survival of mammalian cells
during development; it also plays important roles in regulating
neuronal plasticity and inﬂammatory responses14,16. Inhibition of
ERK phosphorylation decreased the nociceptive behavior in mon-
oarthritic rat ankle joints, suggesting that ERK phosphorylation in
spinal cord neurons plays an important role in chronic inﬂamma-
tory articular pain and that its inhibition may provide signiﬁcant
antinociception51. Glucosamine sulfate could ameliorate OA
development, improve nociception, and decrease p38 and JNK, but
increase the ERK expression level in the articular cartilage in rat OA
models22. Another study reported that phosphorylation of p38 and
JNK17,18 was higher in human OA lesions than in normal tissue
whereas phosphorylated ERK was found equally in both18. In our
present study, we observed increased p38 and JNK expression in
the OA group but no signiﬁcant difference in ERK expression be-
tween the OA and sham groups. Treatment with meloxicam
decreased the expression of p38 and JNK in OA cartilage chon-
drocytes. More interestingly, treatment with meloxicam increased
ERK expression in both the OA þmeloxicam and meloxicam-alone
groups of rats; this is the ﬁrst demonstration that meloxicam
treatment increases ERK expression in both OA-affected and naïve
rat chondrocytes. This observation was partially in line with a
previous report on a dog model of ACLT-induced OA in which p38,JNK, and ERK were all activated to a greater degree in OA lesions
than in normal tissue20. The reasons for the discrepancy with our
results regarding ERK in OA are presently unclear but are most
likely due to differences in cell types or experimental conditions.
We hypothesize that p38, JNK, and ERK might be at least partially
responsible for OA development and nociception. Further work is
needed to better identify the role of the MAPK pathways involved
in OA.
In conclusion, intra-articular administration of meloxicam can
attenuate the development of OA and associated nociceptive
behavior such as secondary mechanical allodynia and altered
weight-bearing distribution in an experimental rat OAmodel. More
interestingly, meloxicam inhibited the expression of p38 and JNK
but enhanced the expression of ERK in the articular cartilage in this
model. These ﬁndings may pave the way for further investigations
of meloxicam as a potential therapy for the treatment of the in-
ﬂammatory component of OA.
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